MoonLake Faces Securities Class Action in SDNY as Firms Push Dec. 15 Lead-Plaintiff Deadline
The case centers on claims that MoonLake overstated sonelokimab’s Nanobody advantages, with the Phase 3 VELA readout undercutting those statements.
Overview
- The putative class action is pending in the Southern District of New York as Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.
- Investor notices from Bleichmar Fonti & Auld, The Rosen Law Firm, and Faruqi & Faruqi highlight a December 15, 2025 deadline to seek lead-plaintiff status.
- The complaint alleges misleading claims about SLK’s purported superiority to monoclonal antibodies, noting overlap with BIMZELX targets IL-17A and IL-17F and disputed tissue-penetration benefits.
- MoonLake reported week-16 Phase 3 VELA results on September 28, 2025, with VELA-2 failing its primary endpoint, and the stock closed at $6.24 on September 29 after a steep decline.
- Notices identify a class period from March 10, 2024 through September 29, 2025, and clarify that no class has been certified and representation is typically on a contingency-fee basis.